
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics Inc is advancing its pipeline of therapies for inherited retinal diseases and other ocular conditions, which includes promising adeno-associated virus-based gene therapies and Phentolamine, a treatment for presbyopia and keratorefractive surgery outcomes. Recent positive topline results from the Phase 3 VEGA-3 trial for phentolamine demonstrated significant improvements in visual acuity, with 17.3% of patients experiencing substantial gains compared to 9.2% for the placebo group. Furthermore, the anticipated sNDA submission for presbyopia in the second half of 2025 reflects Opus Genetics' commitment to innovation and potential market expansion, indicating a robust growth trajectory for the company.
Bears say
Opus Genetics faces significant risks that could negatively impact its financial outlook, particularly the potential failure of its product candidates to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may struggle to secure necessary capital resources for ongoing operations, which could impede program development and commercialization efforts. These factors contribute to a decreased confidence in Opus Genetics's ability to sustain growth and profitability in the competitive ophthalmic biopharmaceutical space.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares